CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Congress Asset Management Co.

Congress Asset Management Co. boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,739 shares of the company’s stock after acquiring an additional 2,971 shares during the quarter. Congress Asset Management Co.’s holdings in CRISPR Therapeutics were worth $2,706,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after acquiring an additional 743,075 shares during the last quarter. State Street Corp lifted its stake in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of CRISPR Therapeutics by 5,269.3% during the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock worth $3,267,000 after buying an additional 81,464 shares during the period. KBC Group NV grew its stake in shares of CRISPR Therapeutics by 2,047.4% in the fourth quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after buying an additional 57,696 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $1,825,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on CRSP. Morgan Stanley lifted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday. Stifel Nicolaus dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Royal Bank of Canada dropped their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Finally, Truist Financial increased their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $74.50.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Stock Up 14.3 %

CRSP opened at $49.72 on Tuesday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10. The business’s 50 day moving average is $41.89 and its two-hundred day moving average is $45.98. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of -17.57 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. Equities analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.